Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study

被引：0
作者：
A. Amraee
M. R. Evazi
M. Shakeri
N. Roozbeh
M. Ghazanfarpour
M. Ghorbani
J. Ansari
L. Darvish
机构：
[1] Iran University of Medical Sciences,Department of Medical Physics, Faculty of Medicine, School of Medicine
[2] Hormozgan University of Medical Science,Hematologist and Medical Oncologist
[3] Tehran University of Medical Sciences,Department of Radiology and Radiotherapy, Allied Medical Sciences School
[4] Hormozgan University of Medical Sciences,Mother and Child Welfare Research Center
[5] Kerman University of Medical Sciences,Department of Midwifery, Razi School of Nursing and Midwifery
[6] Shahid Beheshti University of Medical Sciences,Biomedical Engineering and Medical Physics Department, Faculty of Medicine
[7] Arak University of Medical Sciences,Department of Radiotherapy & Oncology
[8] Hormozgan University of Medical Sciences,Department of Radiology, Faculty of Paramedicine
来源：
Clinical and Translational Oncology | 2019年 / 21卷
关键词：
Checkpoint inhibitor; Nivolumab; Hodgkin lymphoma; PD1 blockade;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1093 / 1103
页数：10
相关论文
共 101 条
[1]  
Makita S(2016)Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma Int J Hematol 104 233-244
[2]  
Maruyama D(2010)Phase II study of ABVd therapy for newly diagnosed clinical stage II–IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305) Int J Hematol 92 713-724
[3]  
Maeshima AM(2008)PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 677-704
[4]  
Ogura M(2010)Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade Semin Oncol 37 430-439
[5]  
Itoh K(2012)Safety and activity of anti-PD-L1 anti-body in patients with advanced cancer N Engl J Med 366 2455-2465
[6]  
Kinoshita T(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2454
[7]  
Keir ME(2013)Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody Clin Cancer Res 19 462-468
[8]  
Butte MJ(2014)Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 20 5064-5074
[9]  
Freeman GJ(2011)Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells Clin Cancer Res 17 4232-4244
[10]  
Weber J(2013)Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial J Clin Oncol 31 4199-4206
12345678910